Inhibition of the cytotoxic effect of *Clostridium difficile* in vitro by *Clostridium butyricum* MIYAIRI 588 strain

Timothy D. H. Woo,1 Kentaro Oka,2 Motomichi Takahashi,2 Fuhito Hojo,1 Takako Osaki,1 Tomoko Hanawa,1 Satoshi Kurata,1 Hideo Yonezawa1 and Shigeru Kamiya1

1Department of Infectious Diseases, Kyorin University School of Medicine, Shinkawa 6-20-2, Mitaka, Tokyo 181-8611, Japan
2Miyarisan Pharmaceuticals, Hanishina-gun, Sakaki-machi 102-15, Nagano 389-0682, Japan

In contrast to most modern pharmaceuticals, probiotics are used in many parts of the world with little or no research data on the complex system of interactions that each strain may elicit in the human body. Research on probiotics has recently become more significant, as probiotics have begun to be prescribed by clinicians as an alternative for some gut infections, especially when antibiotics are contraindicated. This study attempted to elucidate the inhibitory interaction between the Japanese probiotic strain *Clostridium butyricum* MIYAIRI 588 (CBM588) and the hospital pathogen *Clostridium difficile*, which is responsible for a large proportion of antibiotic-associated diarrhoea and colitis. CBM588 has previously shown effectiveness against *C. difficile* in vivo, and here it was found that the toxicity of *C. difficile* in in vitro co-culture with CBM588 was greatly decreased or absent. This was dependent on the inoculation ratio and was not accounted for by the small degree of growth and mRNA inhibition observed. CBM588 and its cell-free supernatant also had no effect on toxin already secreted into the culture medium, and culture of the two strains separated by a semi-permeable membrane resulted in loss of the inhibition. Therefore, it was concluded that the detoxification probably occurred by the inhibition of toxin protein production and that this required close proximity or contact between the two species. The low-pH conditions caused by organic acid secretion were also observed to have inhibitory effects on *C. difficile* growth, metabolism and toxicity.

INTRODUCTION

*Clostridium difficile*-associated disease (CDAD) continues to be a problem in hospitals around the world. Recent UK statistics show an incidence in patients aged over 65 years of over 24 000 cases year\(^{-1}\) at an annual cost of around £103 million (Wilcox et al., 1996). Although the primary cost of disease is increased costs of patient stay and treatment, mortality is also significant, particularly among the elderly (Pépin et al., 2004; Henrich et al., 2009). Infection is usually treated with metronidazole or vancomycin, as most isolates remain susceptible to these antibiotics (Huang et al., 2009), but the most efficient measure to curb *C. difficile* appears to be adequate prophylaxis rather than treatment.

As the growth of *C. difficile* is purported to be due to alterations of the gut flora by antibiotics that normally prevent *C. difficile* spores from germinating (Borrillio & Barclay, 1986; Preidis & Versalovic, 2009), probiotics have been proposed to help rectify the imbalance (Engelbrekston et al., 2009). However, the evidence for probiotics in the treatment of CDAD is not conclusive. Several clinical trials have shown positive effects of various probiotics – commonly *Lactobacillus rhamnosus* GG (Segarra-Newnham, 2007) and *Saccharomyces boulardii* (McFarland, 2010) – but many trials are inconclusive or show marginal effects. Common problems are inconsistencies with dosing, outcome measure and treatment period, as well as dropouts during follow-up, preventing general conclusions of efficacy from being drawn (McFarland, 2009).

*Clostridium butyricum* MIYAIRI 588 (CBM588) is a Japanese probiotic strain isolated from a patient in 1933 that is currently sold commercially. Like *C. difficile*, CBM588 is a Gram-positive obligate anaerobe, but it grows faster and utilizes a wider range of substrates. It produces large quantities of short-chain fatty acids (SCFAs) (deVos et al., 2009), especially butyrate, and an active bacteriocin (Nakanishi & Tanaka, 2010); it also sporulates, allowing it to resist antibiotics that may disrupt other gut flora. It has
previously shown effectiveness in the prophylaxis of CDAD in a mouse model (Kamiya et al., 1997) and in a clinical trial for prevention of antibiotic-associated diarrhoea in paediatric patients (Seki et al., 2003). In another clinical trial, CBM588 significantly reduced the incidence of detection of C. difficile toxin in the stools of patients taking Helicobacter pylori-eradication therapy (Imase et al., 2008). All of these data make CBM588 an interesting candidate for CDAD prophylaxis and so, in this study, we attempted to investigate this inhibitory effect in vitro.

METHODS

Bacterial strains and culture conditions. C. difficile VPI 10463, the reference strain against which new toxinoctypes are compared, was used in this study. This strain produces large amounts of toxin that are easily measurable by Western blot. Clinical isolates including TMG-10, KY-8, KY-34, KY-104 and SLC were isolated in this laboratory. Additionally, KZ-1692, a non-toxigenic strain, was isolated previously (Nakamura et al., 1980). CBM588 was kindly provided by Miyarisan Pharmaceutical Co. Strains were grown and maintained using GAM broth (Nissui Pharmaceuticals) containing 0.1 % (w/v) sodium thioglycolate as reducing agent, GAM agar containing 0.1 % (w/v) sodium taurocholate (Nakarai) or PYG broth (containing 3 % trypticase peptone, 2 % yeast extract, 1 % glucose and 0.1 % sodium thioglycolate). Where indicated, GAM broth was buffered by adding 70 mM phosphate buffer to a final pH of 7.0. Cultures were incubated at 37 °C in an anaerobic chamber using 10 % CO2, 10 % H2 and N2 to balance.

Preparation of spore suspensions. Overnight cultures of C. difficile and CBM588 were inoculated at 1 : 1000 into 40 ml fresh medium. These cultures were incubated for 1 week in an anaerobic chamber at 37 °C. To isolate spores, the cultures were centrifuged at 5000 × g for 10 min to pellet the cells and washed twice with sterile 0.01 M PBS (pH 7.2). The resulting pellet was resuspended in 4 ml sterile PBS and heated to 70 °C for 10 min to inactivate vegetative cells. Spores were then counted using dilution plating on GAM agar with 0.1 % taurocholate, and stored at −30 °C.

Co-culture, supernatant and killed-cell experiments. Routinely, C. difficile and CBM588 overnight cultures were inoculated at 1 : 1000 into fresh medium for culture experiments. For monoculture experiments, the cell number was ascertained at intervals by dilution plating onto GAM agar containing 0.1 % taurocholate. For co-culture experiments, overnight cultures were diluted to 1 : 100 and 1 : 100 000 in fresh medium and inoculated at ratios of 1 : 1, 1 : 100 and 1 : 10 000. For spore co-culture experiments, thawed spore suspensions were inoculated together into GAM broth to a final CBM : C. difficile ratio of 1 : 1000 and then incubated at 37 °C in an anaerobic chamber as above to allow the spores to germinate. At the time periods indicated, 1 ml samples were taken for a cytotoxicity assay and for Western blotting. For dialysis membrane isolation experiments, CBM588 and C. difficile were inoculated on different sides of a cellulose membrane (Sanko) with a maximum pore size of 14 kDa.

Supernatants of C. difficile, CBM588 or co-cultures were prepared by centrifuging 48 h cultures at 5000 × g for 10 min and filtering through 0.22 μm filters (Millipore) to sterilize. Supernatants used for subsequent culture experiments were adjusted to pH 7 using 1 M NaOH and mixed with fresh medium to the required concentrations before inoculation. The effect of CBM588 on C. difficile toxin was tested by inoculating overnight cultures at 1 : 1000 into pH-adjusted 48 h C. difficile cell-free supernatant. Samples were taken at 24, 48 and 72 h for the cytotoxicity assay.

Killed cells of CBM588 were prepared by autoclaving overnight cultures at 105 °C for 15 min or by incubating pelleted cells in 2.5 % glutaraldehyde (v/v) at room temperature for 1 h. Pellets were washed three times in sterile PBS. Cell fragments were prepared by bead-beating cell pellets suspended in PBS with 0.1 mm glass beads in a multihead-beater (Yasui Kikai). The supernatant was sterilized by filtering through a 0.22 μm filter (Millipore). Preparations were inoculated into cultures at 0 and 24 h at 10−6-10−4 cells ml−1.

pH-adjustment experiments and HPLC. Buffered culture medium was adjusted to the appropriate pH using 1 M NaOH or 1 M HCl. Toxin-inactivation assays were performed using crude toxin isolated by 0.22 μm filtration of 48 h C. difficile supernatant. Crude toxin was adjusted to the required pH and incubated at 37 °C. Aliquots were withdrawn every 2 h for the cytotoxic assay. HPLC of organic acid concentrations was performed at various time intervals using an LC-6A HPLC system (Shimadzu) with a Shim-pack SCR-102H column and a CCD-6A electroconductivity detector. For this and the growth-inhibition experiments, the statistical significance of the results was calculated by a paired-sample t-test, with P<0.05 being considered significant.

Cytotoxicity assay. The African green monkey kidney cell line Vero S1 has been documented previously as a sensitive indicator of C. difficile toxin activity (Welch et al., 1985). Briefly, cells were maintained in minimum essential medium (Sigma Aldrich) containing 10 % fetal bovine serum (Sigma Aldrich) in flasks or 96-well plates. For the cytotoxicity assay, the cell-culture medium was removed and replaced with fresh cell-culture medium or dilutions of cell-free supernatants (diluted from 1:12.5 to 1:104 857 600). Cells were incubated at 37 °C in 5 % CO2 overnight and viewed under a light microscope. The cytotoxicity of the supernatant was determined by the lowest concentration resulting in >50 % cell rounding. This value is referred to as the CD50 for the sample. Cytotoxicity experiments were repeated at least three times.

Western blotting. Culture samples (1 ml) for Western blot were centrifuged at 10 000 × g for 5 min to pellet the cells and the supernatant was removed to a fresh tube. The pellet was then washed with 0.01 M PBS to remove excess supernatant and the cells were lysed using 2 mg lysozyme ml−1 at 37 °C for 1 h. The supernatant was filtered through a 0.22 μm filter to remove any remaining bacterial cells. The pellet and supernatant samples were then mixed 1 : 1 with 2 × SDS loading buffer containing DTT (ATTO) and heated for 5 min in a boiling water bath. Samples were stored at −30 °C before use. A 30 μl aliquot of each thawed sample was run for 120 min at 20 mA on an SDS 5–20 % gradient polyacrylamide gel and then transferred to PVDF membranes for 45 min at 0.22 mA. Membranes were blocked in 5 % skimmed milk in PBS with 0.1 % Tween 20 overnight. Goat primary antibody to C. difficile toxin B was obtained from Techlab. Blocked membranes were incubated with primary antibody at a 1:1 000 dilution in PBS with 0.1 % Tween 20 for 40 min, followed by secondary horseradish peroxidase-conjugated donkey anti-goat IgG (Santa Cruz Biotechnologies) diluted 1:10 000 in PBS with 0.1 % Tween 20 for 30 min, washing with four changes of PBS with 0.1 % Tween 20 for 20 min between each incubation. Bound antibody was visualized using an Amersham ECL Plus Western blotting system (GE Healthcare) according to the manufacturer’s protocol.

Real-time PCR. Real-time PCR was used to quantify toxin mRNA levels and to ascertain cell numbers in co-culture experiments, as no selective agar could be found to differentiate the two strains. Primers for toxin A and toxin B were used for both mRNA and cell-number quantification and are shown in Table 1, together with the conditions used for each PCR. RT-PCR has been shown previously to accurately quantify individual species of bacteria in complex co-culture mixes such as faecal samples (Matsuki et al., 2004) and to enumerate
Table 1. Oligonucleotides used in this study

<table>
<thead>
<tr>
<th>Name*</th>
<th>Sequence (5’→3’)</th>
<th>Target size (bp)</th>
<th>T_m (°C)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>TcdA-F</td>
<td>GGGGGATCACGGACACACAGTGAC</td>
<td>196</td>
<td>68.0</td>
<td>This study</td>
</tr>
<tr>
<td>TcdA-R</td>
<td>GGAACCTGCTCCAGTTCCCAACCA</td>
<td>156</td>
<td>58.0</td>
<td>Lee &amp; Song (2005)</td>
</tr>
<tr>
<td>TcdB-F</td>
<td>CACTTCTTTTCGACACATCAA</td>
<td>–</td>
<td>56.7</td>
<td>This study</td>
</tr>
<tr>
<td>TcdB-R</td>
<td>TGCCACATCCCTTTCCCAAG</td>
<td>–</td>
<td>50.1</td>
<td>This study</td>
</tr>
</tbody>
</table>

*TcdA and TcdB primers are specific to the tcdA and tcdB gene loci, respectively. F, Forward primer; R, reverse primer. RTR primers are gene-specific primers used for reverse transcription.

In order to test the effect of co-culture on toxicity, the highly toxigenic *C. difficile* VPI 10463 strain or the clinical isolate TMG-10 were co-cultured at a ratio of 1:1 with CBM588, which resulted in a complete loss of toxicity at 24 h compared with the monoculture control. To test further the effect of dosage, *C. difficile* VPI 10463 was cultured with CBM588 at various BM: *C. difficile* inoculation ratios from 10,000:1 to 1:1000. Cytotoxicity at 24 h in coculture was not detected when CBM588 was present at a concentration equal to or in excess of *C. difficile*, and was greatly reduced even if *C. difficile* was in excess (Table 2). This reduction in cytotoxicity continued at 48 h, indicating that it was a long-term effect, and addition of fresh medium at 24 h had no effect on this inhibition, suggesting that nutrient depletion was not the main cause (data not shown). Western blots showed that there was very little toxin build-up inside the bacterial cells, which mirrored the lack of toxin in the supernatant in these samples (Fig. 1). It was observed that toxin tended to build up inside *C. difficile* cells before release into the supernatant began at a certain time point in the growth phase.

**RESULTS AND DISCUSSION**

**Co-culture causes complete and persistent loss of toxicity**

It is well-documented that *C. difficile* can be inhibited when co-cultured with other gut bacteria. For example, faecal emulsions from well patients inhibit *C. difficile* growth and toxicity *in vitro* (Borriello & Barclay, 1986; Yamamoto-Osaki *et al.*, 1994). Previous studies on other probiotics have also reported growth and toxicity inhibition in co-culture with various species of *Bifidobacterium* and *Lactobacillus* (Banerjee *et al.*, 2009; Trejo *et al.*, 2010). CBM588 in particular has been shown to inhibit *C. difficile* growth in co-culture towards other pathogenic bacteria such as *Escherichia coli* O157 (Takahashi *et al.*, 2004) and *H. pylori* (Takahashi *et al.*, 2000) and additionally has the effect of supporting the growth of the gut’s endemic *Lactobacillus* species (Ichikawa *et al.*, 1999).

**Growth and toxin mRNA in co-culture exhibit a dose-dependent inhibition**

The substances previously implicated in the inhibitory effect by CBM588 were SCFAs, particularly butyric acid, which was shown to be toxic even at a neutral pH. However, as *C. difficile* also produces butyric acid, we did not expect this to be the cause of the inhibition in this case. In fact, previous research on toxin regulation showed that butyrate not only fails to affect growth, but actually increases toxin yield (Karlsson *et al.*, 2003).

Growth of the two strains in co-culture when the number of *C. difficile* cells was equal to or greater than that of CBM588 showed no growth inhibition for either VPI 10463 or TMG-10. However, when CBM588 was in excess of *C. difficile* in the co-culture medium, a degree of inhibition proportional to the inoculation ratio was observed. Inoculation ratios of 100:1 and 10,000:1 caused growth inhibition of approximately 10- and 100-fold, respectively (Fig. 2a). This was similar to the results obtained in a previous mouse-model study where administration of CBM588 resulted in a 10- to 100-fold reduction in *C. difficile* growth and toxicity.
100-fold reduction in *C. difficile* growth (Kamiya et al., 1997).

However, when spores of both CBM588 and *C. difficile* were inoculated, a greater inhibitory effect was observed over 24 h. *C. difficile* viable cell numbers decreased by approximately 100-fold over the initial 9 h when CBM588 was in the exponential phase, but increased once CBM588 reached the stationary phase to give a 10-fold difference at 24 h (Fig. 2b). In contrast to vegetative CBM588, which required a 10 000 : 1 inoculation ratio to exhibit this 100-fold inhibition in the 10 000 : 1 culture would account for the inhibition observed during the experiment. Both transcript and secretory molecule levels increased 50-fold in the 10 000 : 1 culture, consistent with the growth inhibition observed during the experiment. Both transcript levels decreased by approximately 50-fold and 5000-fold in 100 : 1 and 10 000 : 1 culture ratios, respectively, relative to an equivalent *C. difficile* monoculture control (Table 3). As mRNA expression is heavily dependent on growth phase (Hundsberger et al., 1997), the greater degree of growth inhibition in the 10 000 : 1 culture would account for the slower production of toxin mRNA in these samples. Interestingly, both *tcdA* and *tcdB* transcripts were normal or growth inhibition, CBM588 spores not only achieved this after 9 h, but reduced the number of viable *C. difficile* spores in the culture medium. This occurred even at low inoculation ratios of 1 : 1000, suggesting that low doses of CBM588 spores could inhibit *C. difficile* germination successfully in the gut. From these results, it appeared that CBM588 was more efficient at inhibiting the growth of spores or preventing spore germination than the growth of vegetative cells, and that the recovery of *C. difficile* cell numbers after 9 h could be attributed to the increased proportion of vegetative *C. difficile* in the medium. The inhibitory effect could in this case be caused by the large quantities of organic acids secreted by CBM588. As CBM588 germinates and doubles at nearly twice the rate of *C. difficile* (K. Oka & M. Takahashi, unpublished data), it will start to secrete organic acids while *C. difficile* is still germinating. Organic acids such as vinegar and lemon juice are already known to inhibit spore germination in *Clostridium perfringens* (Valenzuela-Martinez et al., 2010), so we would expect butyric acid to have a similar effect on *C. difficile* spore germination in this case.

Toxin mRNA levels have been shown to respond to a variety of environmental signals such as temperature, nutrient concentrations and antibiotics (Karlsson et al., 1999, 2003; Yamakawa et al., 1998; Nakamura et al., 1982). We checked for the downregulation of toxin mRNAs by nutrient depletion or other signalling molecules using real-time PCR. However, mRNA levels of *tcdA* and *tcdB* transcripts during co-culture showed only a small reduction, consistent with the growth inhibition observed during the experiment. Both transcript levels decreased by approximately 50-fold and 5000-fold in 100 : 1 and 10 000 : 1 culture ratios, respectively, relative to an equivalent *C. difficile* monoculture control (Table 3). As mRNA expression is heavily dependent on growth phase (Hundsberger et al., 1997), the greater degree of growth inhibition in the 10 000 : 1 culture would account for the slower production of toxin mRNA in these samples. Interestingly, both *tcdA* and *tcdB* transcripts were normal or...
increased by up to 30-fold relative to the control if *C. difficile* was equal to or in excess of CBM588, even though the cell counts of *C. difficile* in these cultures were equivalent to the control monocultures (Fig. 2a), which we ascribed to upregulation by increased butyric acid in the medium. Therefore, it was clear that the reduction in cytotoxicity occurred as a result of the lack of mature toxin and was not caused by a significant reduction in gene transcription.

**Inhibition of toxicity in co-culture appears to require cell contact**

Previous studies have suggested that probiotics may release substances into the supernatant that inhibit toxin production or adhesion to colonocytes (Banerjee *et al.*, 2009) or that destroy mature toxin (Castagliuolo *et al.*, 1999). One study also considered the role of quorum sensing, although this has been shown to have at most a minor effect on toxin production (Lee & Song, 2005; Carter *et al.*, 2005), and our preliminary studies found very low LuxS/AI-2 activity in CBM588 (data not shown).

However, pH-neutral CBM588 supernatant was found to have no effect on the growth of the TMG-10, KY-8, KY-34, KY-104 and SLC clinical isolates of *C. difficile* or the reference strain VPI 10463 (data not shown) and only a slight effect on toxicity. When compared with the effect of supernatant isolated from the non-toxigenic KZ-1692 strain of *C. difficile*, there was no significant difference in growth or toxin production.

**Table 3.** Relative toxin mRNA levels at different inoculation ratios

mRNA values are shown relative to an equivalent *C. difficile* monoculture control. Absolute mean mRNA quantity values for *tdxA* controls were $4.23 \times 10^4$ for a ratio of 1:1 and below of CBM: *C. difficile*, $8.61 \times 10^4$ for 100:1 and $4.92 \times 10^5$ for 10 000:1; and for *tdxB* were $2.01 \times 10^4$ for 1:1 and below, $3.13 \times 10^4$ for 100:1 and $1.89 \times 10^5$ for 10 000:1. All values shown are the mean of three independent experiments. The lowest and highest values observed are shown in parentheses. Growth data for this experiment are shown in Fig. 2(a).

<table>
<thead>
<tr>
<th>Inoculation ratio</th>
<th>Relative mRNA level at 24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>C. difficile</em></td>
</tr>
<tr>
<td>CBM588</td>
<td></td>
</tr>
<tr>
<td>10 000</td>
<td>1</td>
</tr>
<tr>
<td>100</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>100</td>
</tr>
<tr>
<td>1</td>
<td>10 000</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fig. 2.** Co-culture with CBM588 causes mild dose-dependent growth inhibition of *C. difficile*. Dose-dependent growth inhibition of *C. difficile* was observed in co-culture with both vegetative cells (a) and spores (b) of CBM588. In the case of vegetative cells, there was no difference at a 1:1 (CBM: *C. difficile*) ratio (data not shown). At 24 h, at 100:1 (■, co-culture; □, control), approximately tenfold inhibition was seen, whilst at 10 000:1 (▲, co-culture; △, control), approximately 100-fold inhibition was seen. In the case of spores (■, co-culture; □, control), a greater inhibition was seen, even at a low inoculation ratio of 1:1000, where *C. difficile* declined over the initial 9 h while CBM588 (▼) was in the exponential phase. Results shown are means ± SEM of at least three independent experiments. *Statistically significant decrease compared with the control (P<0.05).
(Fig. 3). In this case, the difference in toxicity was likely to be due to nutrient depletion, as *C. difficile* is only able to metabolize simple nutrients and we would therefore expect that the use of a depleted cell-free supernatant would impair its metabolism.

Culture of the two strains separated by a permeable cellulose membrane (pore size <14 kDa) also showed no inhibition of *C. difficile* toxicity. In order to confirm whether the presence of *C. difficile* cells in the CBM588 culture affected the secretion of an inhibitor substance, the experiment was repeated using a co-culture of CBM588 and *C. difficile* VPI 10463 instead of CBM588 monoculture (clostridial toxins are much larger than the membrane cut-off and do not pass through the dialysis tubing). However, this too showed normal toxicity. This suggests strongly that the co-culture inhibitory effect is not governed by a secreted molecule and cannot be due to nutrient depletion, as simple nutrients diffuse freely through the membrane.

This led us to hypothesize that the effector molecule may be present on the cell surface of CBM588, but attempts to elicit the same response with CBM588 cells killed by glutaraldehyde or heat, or on cells fragmented by bead beating, were unsuccessful. However, these methods greatly denature the membrane proteins, and filtration of cell fragments may result in retention of most of the cell material. Unfortunately, no other more suitable methods for testing this were available to us at the time.

Studies on the probiotic yeast *S. boulardii* have found that it inhibits *C. difficile* toxin *in vitro* by secreting a protease that degrades the mature protein (Castagliuolo et al., 1999) and also by modulating the gut immune response (Chen et al., 2006; Kyne et al., 2001). However, data on the recently sequenced genome of CBM588 show that, although it contains protease genes, none of them is confirmed as being secreted (unpublished data). Accordingly, we found that neither live CBM588 nor its cell-free supernatant had a detoxifying effect on sterile samples of *C. difficile* toxin. CBM588 has shown beneficial effects on colonic inflammation in a rat dextran sulphate colitis model, reportedly by increased production of SCFAs in the colon (Okamoto et al., 2000) and enhancement of host *Lactobacillus* species (Ichikawa et al., 1999). It is therefore possible that this effect accounts partly for the previous *in vivo* results, but it would not account for the observations in this study.

We concluded from this that inhibition of toxicity is not governed by a secreted factor, as with many other probiotics, but appears to rely instead on an as-yet-uncharacterized cell–cell interaction between the two species.

**Low-pH conditions inhibit *C. difficile* growth and toxicity**

*C. difficile* is highly adapted to the human gut environment and, as such, 48 h cultures of *C. difficile* generally exhibit pH values of around 6.2, similar to the gut pH. Similar cultures of CBM588 have a much lower pH of around 4.9, with co-cultures generally exhibiting a pH of 4.9–5.2. This low pH is caused by the large quantity of organic acids produced by this strain. SCFAs such as butyrate also act as an energy source for colonocytes and have been shown to be beneficial in other forms of colitis (Scheppach et al., 1992), as well as in the possible prevention of colon cancer (McIntyre et al., 1993; Scharlau et al., 2009).

---

**Fig. 3.** Effect of CBM588 cell-free supernatant and pH on *C. difficile* toxicity. (a) The effect of various concentrations of pH-adjusted CBM588 cell-free supernatant at 48 h (shaded bars) is expressed as mean log values ± SEM relative to a 0% control (no added supernatant). The equivalent mean result (filled bars) of the supernatant of the non-toxigenic strain *C. difficile* KZ-1692 was used for comparison. The CD values of the control cultures were 1:800 at 24 h and 1:2.46×10^6 at 48 h. (b) The effect of pH on *C. difficile* monoculture at 24 h (light grey bars) and 48 h (dark grey bars) is expressed as mean log values ± SEM relative to pH 6.5. The Western blot of pH-adjusted cultures is shown in Fig. 4(c). The CD values of the control cultures were 1:800 at 24 h and 1:2.46×10^6 at 48 h. All values shown are the mean of three independent experiments.
We measured the growth and toxicity of *C. difficile* VPI 10463 strain monocultures at a pH range of 4.5–8.5 to assess the effect of pH on this strain, as it exhibits the greatest toxin production, facilitating comparison by Western blotting. Growth of *C. difficile* at pH 4.5 was negligible (not shown) and growth at pH 5.5 was markedly reduced, although it reached the same level as the control at pH 6.5 after 24 h (Fig. 4a). Growth at pH ≥ 6.5 was normal. HPLC measurement of organic acid production at pH 5.5 found a significant 8-fold reduction in total acids produced at 24 h compared with the control at pH 6.5 (Fig. 4b). Toxin production as measured by Western blotting (Fig. 4c) and a cytotoxic assay (Fig. 3) showed that intracellular toxin levels at 48 h were highest at pH 7.5. *C. difficile* toxin B was shown previously to require an acidic endosome for activity during endocytosis and it was found that extracellular low pH can substitute for this effect (Qa'Dan *et al.*, 2000). Results from the same study also indicated that maintenance of toxin in a low-pH environment reduced its cytotoxicity, although it was not clear whether this was a reversible effect. We observed that raw *C. difficile* toxin B in a cell-free supernatant incubated at 37 °C, at a pH of <6.0, decreased steadily in cytotoxicity (Fig. 4d), which may be due to irreversible conformational changes of the toxin B molecule, causing it to be unable to bind to membrane receptors. Western blotting showed band widening and blurring, possibly due to degradation of the misfolded toxin (Fig. 4e).

We concluded that the low pH in co-cultures probably had a significant effect on both the growth and the observed efficacy of toxin B. This may also have affected previous studies on *Lactobacillus* and *Bifidobacterium* as these strains also produce organic acids and it was not clear whether the pH was controlled in these studies.

**Toxin inhibition persists at colonic pH**

In order to control for pH changes during co-culture, GAM broth was buffered with 70 mM phosphate buffer at pH 7.0. This was the highest concentration of potassium tolerated by both strains with no growth inhibition. Over 24 h, the pH of the buffered medium decreased to 5.8–5.9 and was maintained at this level. This is similar to the pH in the large intestine in humans, which ranges from 5.6 to 6.8 (Wilson, 2005). In this buffered environment, co-culture excess of CBM588 at 100 : 1 and 10 000 : 1 ratio inoculations continued to exhibit little or no toxin production at 24 and 48 h. When *C. difficile* was inoculated at the same level or in excess relative to CBM588 (ratios of 1 : 1, 1 : 100 and 1 : 10 000), supernatants at 24 h showed equal or slightly increased cytotoxicity relative to controls, consistent with an increase in toxin production due to a combination of butyric acid concentration and a higher starting pH. However, supernatants at 48 h showed a stark reduction in relative cytotoxicity, and this was supported by a reduction in toxin yield as shown by Western blotting. At ratios of 1 : 1, 1 : 100 and 1 : 10 000,
toxicity was decreased by 4000-, 1300- and 700-fold, respectively (Table 2; Fig. 1).

This result showed that the effect of low pH did not account for the previously observed inhibition, although it did have a synergistic effect. The exact mechanism of inhibition was not clarified by our investigation, but we were able to conclude that CBM588 appeared to interfere with protein production in _C. difficile_ and the mechanism appeared to require cell contact. As the supernatant alone had no effect in our study, if a secreted factor is responsible, it would have to be both short-lived and <14 kDa, or be active only at acidic pH. It was also observed that toxin was released into the medium earlier in some co-cultures, although intracellular toxin levels did not build up afterwards as in the controls. As toxin is thought to be released via a holing–endolysin reaction by TcdE (Tan et al., 2001), it is tempting to postulate that CBM588 may speed up membrane permeabilization before toxin maturation occurs. However, further research is required to elucidate which, if any, of these is the case.

**Conclusions**

The action of CBM588 _in vitro_ was shown not to occur by previously documented methods of growth inhibition, mRNA downregulation or extracellular toxin inactivation; instead, cell contact in co-culture appeared to affect _C. difficile_ toxin protein production, which may represent a novel inhibitory mechanism.

From the results of this study, it is clear that the commercially available spore preparation of CBM588 would work best as a prophylactic medication for CDAD, as both growth and toxin inhibition work better at higher inoculation ratios. Additionally, we have shown that even low quantities of CBM588 spores are capable of inhibiting the germination of much larger quantities of _C. difficile_. There are also clinical benefits in the use of a probiotic such as CBM588 over currently used preparations of _Lactobacillus_ and _Bifidobacterium_ species. As it is not feasible to refrigerate all doses of a probiotic before giving them to patients, an often-cited reason for non-compliance is the taste of the yoghurt-drink preparations of these bacteria. As CBM588 is only available as spores in tablet form, this would not be a problem and doses would be easier to measure. To date, CBM588 has an excellent safety record, although cases of probiotic infections are generally very rare (Boyle et al., 2006). Being able to sporulate also allows CBM588 to resist the action of antibiotics that would inhibit other probiotic strains. In terms of cost, a 20 day supply of CBM588 costs approximately £20, which is comparable to other commercial probiotics, and it has a far longer shelf-life at room temperature.

Although probiotics continue to be used in the management of CDAD, their mechanism of action remains poorly understood. This, combined with the dizzying array of probiotic strains and preparations available, makes formulation and assessment of treatment regimens a challenging task. More studies investigating the interactions of probiotic strains in combination with larger cohort trials are required before clinicians are able to decide in which cases they are suitable and which probiotics to prescribe.

**ACKNOWLEDGEMENTS**

This research was completed under a research scholarship provided by MEXT: The Ministry of Education, Culture, Sports, Science and Technology for Japan.

**REFERENCES**


Anaerobe 15, 2202–2222.


